MNCs for Bone Marrow Failure After Malignant Diseases Children Chemotherapy
Cord
About this trial
This is an interventional treatment trial for Cord focused on measuring bone marrow failure, pediatric chemotherapy, mononuclear cells
Eligibility Criteria
Inclusion Criteria: Age ≤ 17 years old; Treated in pediatric hematology department from September 2021 to September 2024, patients with bone marrow failure after transplantation; Eastern Cooperative Oncology Group(ECOG) score ≤ 2; Sign the informed consent form (< 10 years old, signed by the guardian; ≥ 10 The children and their guardians signed the informed consent form before the selection. Exclusion Criteria: Those who have received thoracic radiotherapy in the past; Those who do not meet the above inclusion criteria.
Sites / Locations
- Pediatrics, Qianfoshan HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Experimental group
control group
granulocyte stimulating factor(5ug/kg/d) +infusion of umbilical cord blood mononuclear cells, each infusion ≥1×10^8, once a week
granulocyte stimulating factor 5ug/kg/d